{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T01:21:23Z","timestamp":1775006483447,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018890","name":"Dutch Cardiovascular Alliance","doi-asserted-by":"publisher","award":["01-002-2022-0118 EmbRACE"],"award-info":[{"award-number":["01-002-2022-0118 EmbRACE"]}],"id":[{"id":"10.13039\/100018890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Pacing and Electrophysiology Journal"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ipej.2025.11.014","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:49:57Z","timestamp":1764607797000},"page":"61-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Edoxaban for stroke prevention in patients with atrial fibrillation: Of randomized and real-world evidence"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8122-7017","authenticated-orcid":false,"given":"Joris R.","family":"de Groot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ipej.2025.11.014_bib1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/s41569-024-01091-1","article-title":"The burden of atrial fibrillation in the Asia-Pacific region","volume":"21","author":"Wong","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ipej.2025.11.014_bib2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials","volume":"154","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ipej.2025.11.014_bib3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ipej.2025.11.014_bib4","doi-asserted-by":"crossref","first-page":"426s","DOI":"10.1378\/chest.102.4_Supplement.426S","article-title":"Antithrombotic therapy in atrial fibrillation","volume":"102","author":"Laupacis","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.ipej.2025.11.014_bib5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ipej.2025.11.014_bib6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ipej.2025.11.014_bib7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ipej.2025.11.014_bib8","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ipej.2025.11.014_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ipej.2025.11.014_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ipej.2025.11.014_bib11","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ipej.2025.11.014_bib12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ipej.2025.11.014_bib13","first-page":"1847","article-title":"The 2020 Canadian cardiovascular society\/canadian heart rhythm society comprehensive guidelines for the management of atrial fibrillation","volume":"36","author":"Andrade","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ipej.2025.11.014_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ahj.2017.08.018","article-title":"Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry","volume":"198","author":"Huisman","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.ipej.2025.11.014_bib15","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/eurheartj\/ehw233","article-title":"Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF","volume":"37","author":"Bassand","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ipej.2025.11.014_bib16","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ipej.2025.11.014_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ahj.2021.12.017","article-title":"Edoxaban versus warfarin in high-risk patients with atrial fibrillation: a comprehensive analysis of high-risk subgroups","volume":"247","author":"Gencer","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.ipej.2025.11.014_bib18","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jacc.2016.06.034","article-title":"Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis","volume":"68","author":"Steffel","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ipej.2025.11.014_bib19","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1161\/STROKEAHA.116.013540","article-title":"Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48)","volume":"47","author":"Rost","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.ipej.2025.11.014_bib20","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1161\/STROKEAHA.114.006025","article-title":"Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48","volume":"45","author":"Giugliano","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.ipej.2025.11.014_bib21","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1540-8159.2007.00745.x","article-title":"Intramyocardial pacing and sensing for the enhancement of cardiac stimulation and sensing specificity","volume":"30","author":"Asirvatham","year":"2007","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.ipej.2025.11.014_bib22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ipej.2025.11.014_bib23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ahj.2021.01.013","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: a secondary analysis of the ENGAGE AF-TIMI 48 study","volume":"235","author":"de Groot","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.ipej.2025.11.014_bib24","article-title":"Efficacy and safety of renal function on edoxaban versus warfarin for atrial fibrillation: a systematic review and meta-analysis","volume":"10","author":"Wang","year":"2023","journal-title":"Medicines (Basel)"},{"key":"10.1016\/j.ipej.2025.11.014_bib25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1055\/s-0040-1716540","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation at the extremes of body weight: an analysis from the ENGAGE AF-TIMI 48 trial","volume":"121","author":"Boriani","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ipej.2025.11.014_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031506","article-title":"Efficacy and safety of low-dose edoxaban by body weight in very elderly patients with atrial fibrillation: a subanalysis of the randomized ELDERCARE-AF trial","volume":"13","author":"Akao","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ipej.2025.11.014_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)31474-X","article-title":"Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial","author":"Goette","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ipej.2025.11.014_bib28","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ipej.2025.11.014_bib29","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ipej.2025.11.014_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44345-7","article-title":"Edoxaban in patients with non-valvular atrial fibrillation after percutaneous coronary intervention: ENCOURAGE-AF design","volume":"13","author":"Baldus","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ipej.2025.11.014_bib31","first-page":"176","article-title":"Edoxaban in atrial fibrillation patients with established coronary artery disease: insights from ENGAGE AF-TIMI 48","volume":"8","author":"Zelniker","year":"2019","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.ipej.2025.11.014_bib32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2459\/JCM.0000000000000737","article-title":"Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study","volume":"20","author":"De Caterina","year":"2019","journal-title":"J Cardiovasc Med"},{"key":"10.1016\/j.ipej.2025.11.014_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/clc.70091","article-title":"Two-year Follow-Up of patients with atrial fibrillation receiving edoxaban in routine clinical practice: results from the global ETNA-AF program","volume":"48","author":"De Caterina","year":"2025","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ipej.2025.11.014_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132118","article-title":"Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study","volume":"408","author":"Kirchhof","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ipej.2025.11.014_bib35","doi-asserted-by":"crossref","first-page":"f30","DOI":"10.1093\/ehjcvp\/pvaa079","article-title":"Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study","volume":"7","author":"de Groot","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ipej.2025.11.014_bib36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12471-020-01518-7","article-title":"Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study","volume":"29","author":"de Vries","year":"2021","journal-title":"Neth Heart J : Monthly J Netherlands Soc Cardiol Netherlands Heart Foundation"},{"key":"10.1016\/j.ipej.2025.11.014_bib37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12872-019-1144-x","article-title":"Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)","volume":"19","author":"De Caterina","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ipej.2025.11.014_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/ehjcvp\/pvac042","article-title":"Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care","volume":"9","author":"Kirchhof","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ipej.2025.11.014_bib39","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/europace\/euac004","article-title":"Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis","volume":"24","author":"Diemberger","year":"2022","journal-title":"Europace:"},{"key":"10.1016\/j.ipej.2025.11.014_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100880","article-title":"Incidence and predictors of worsening renal function in edoxaban-treated atrial fibrillation patients within ETNA-AF-Europe registry","volume":"3","author":"Gwechenberger","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.ipej.2025.11.014_bib41","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/eurheartj\/ehy807","article-title":"Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial","volume":"40","author":"Chao","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ipej.2025.11.014_bib42","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jacc.2018.05.066","article-title":"Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety","volume":"72","author":"Lee","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ipej.2025.11.014_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/joa3.13212","article-title":"Two-year clinical outcomes of Taiwanese and other Asian ethnicities with atrial fibrillation treated with edoxaban in the ETNA-AF Asia registry","volume":"41","author":"Wang","year":"2025","journal-title":"J Arrhythm"},{"key":"10.1016\/j.ipej.2025.11.014_bib44","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1253\/circrep.CR-23-0098","article-title":"Prescribing patterns and outcomes of Edoxaban in atrial fibrillation patients from Asia - one-year data from the global ETNA-AF program","volume":"6","author":"Choi","year":"2024","journal-title":"Circ Rep"},{"key":"10.1016\/j.ipej.2025.11.014_bib45","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1111\/bcp.14623","article-title":"Association of risk factors and bleeding complications in Asian patients taking edoxaban","volume":"87","author":"Lee","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ipej.2025.11.014_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.736826","article-title":"Factors associated with edoxaban concentration among patients with atrial fibrillation","volume":"12","author":"Lin","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ipej.2025.11.014_bib47","article-title":"Cardiovascular and neurological outcomes in patients treated with edoxaban for atrial fibrillation and characteristics in patients with cancer","author":"Cheng","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.ipej.2025.11.014_bib48","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jacc.2020.12.053","article-title":"Randomized, double-blind comparison of half-dose versus full-dose edoxaban in 14,014 patients with atrial fibrillation","volume":"77","author":"Steffel","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ipej.2025.11.014_bib49","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamacardio.2024.1793","article-title":"Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial","volume":"9","author":"Zimerman","year":"2024","journal-title":"JAMA cardiology"},{"key":"10.1016\/j.ipej.2025.11.014_bib50","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.amjmed.2022.05.031","article-title":"Association of antisecretory drugs with upper gastrointestinal bleeding in patients using oral anticoagulants: a systematic review and meta-analysis","volume":"135","author":"Kurlander","year":"2022","journal-title":"Am J Med"}],"container-title":["Indian Pacing and Electrophysiology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0972629225002219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0972629225002219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:16:56Z","timestamp":1775002616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0972629225002219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0972629225002219"],"URL":"https:\/\/doi.org\/10.1016\/j.ipej.2025.11.014","relation":{},"ISSN":["0972-6292"],"issn-type":[{"value":"0972-6292","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Edoxaban for stroke prevention in patients with atrial fibrillation: Of randomized and real-world evidence","name":"articletitle","label":"Article Title"},{"value":"Indian Pacing and Electrophysiology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ipej.2025.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Indian Heart Rhythm Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}